Loop diuretics in anuric hemodialysis patients for the clearance of protein-bound uremic toxins.

IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY
Clinical Kidney Journal Pub Date : 2025-06-14 eCollection Date: 2025-07-01 DOI:10.1093/ckj/sfaf195
Didier Sánchez-Ospina, Maria Romero-Cote, Lucia Criado-Bellido, Maria Isabel Saez-Calero, Badawi Hijazi-Prieto, Sandra Delgado-Cuesta, Francisco Herrera-Gómez, Maddalen Mujika-Marticorena, Emilio Gonzalez-Parra, Maria Jesus Izquierdo-Ortiz, Sebastián Mas-Fontao
{"title":"Loop diuretics in anuric hemodialysis patients for the clearance of protein-bound uremic toxins.","authors":"Didier Sánchez-Ospina, Maria Romero-Cote, Lucia Criado-Bellido, Maria Isabel Saez-Calero, Badawi Hijazi-Prieto, Sandra Delgado-Cuesta, Francisco Herrera-Gómez, Maddalen Mujika-Marticorena, Emilio Gonzalez-Parra, Maria Jesus Izquierdo-Ortiz, Sebastián Mas-Fontao","doi":"10.1093/ckj/sfaf195","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In chronic kidney disease, the accumulation of protein-bound uremic toxins (PBUTs), such as hippuric acid (HA), p-cresyl sulfate (PCS) and indoxyl sulfate (IS), contributes to systemic toxicity and organ dysfunction. These toxins bind to plasma proteins, primarily albumin, rendering them resistant to clearance by conventional dialysis. This study hypothesizes that loop diuretics, particularly torasemide and furosemide, can displace PBUTs from their albumin-binding sites, increasing their free fraction and enhancing their removal during hemodialysis.</p><p><strong>Methods: </strong>This pilot multicenter crossover study included 17 anuric hemodialysis patients recruited from two hospitals. Participants underwent sequential treatment with furosemide and torasemide, each phase separated by a 1-week washout period. Plasma concentrations of HA, PCS and IS were measured pre- and post-dialysis during baseline (no diuretics) and diuretic treatment phases using high-performance liquid chromatography coupled with tandem mass spectrometry. Changes in pre- and post-dialysis toxin levels were evaluated across treatment phases. Repeated measures analysis of variance assessed the effect of each diuretic treatment on toxin levels and clearance rates.</p><p><strong>Results: </strong>Both loop diuretics increased the free fraction and clearance of PBUTs compared with baseline. Torasemide demonstrated higher efficacy in enhancing the clearance of HA (76.8%) compared with furosemide (63.2%) and baseline (57.3%). For PCS, furosemide achieved greater reductions (66.3%) than torasemide (61.8%) and baseline (24%). Indoxyl sulfate clearance increased significantly with both diuretics (59.1% for furosemide and 58.8% for torasemide) compared with baseline (26.2%).</p><p><strong>Conclusion: </strong>This study demonstrates that loop diuretics, especially torasemide, can enhance the clearance of PBUTs during hemodialysis. Their use mobilizes PBUTs from tissue stores and increases their dialyzability. These findings warrant further investigation in larger, long-term studies to validate the efficacy and clinical benefits of this approach.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf195"},"PeriodicalIF":3.9000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264483/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Kidney Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ckj/sfaf195","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In chronic kidney disease, the accumulation of protein-bound uremic toxins (PBUTs), such as hippuric acid (HA), p-cresyl sulfate (PCS) and indoxyl sulfate (IS), contributes to systemic toxicity and organ dysfunction. These toxins bind to plasma proteins, primarily albumin, rendering them resistant to clearance by conventional dialysis. This study hypothesizes that loop diuretics, particularly torasemide and furosemide, can displace PBUTs from their albumin-binding sites, increasing their free fraction and enhancing their removal during hemodialysis.

Methods: This pilot multicenter crossover study included 17 anuric hemodialysis patients recruited from two hospitals. Participants underwent sequential treatment with furosemide and torasemide, each phase separated by a 1-week washout period. Plasma concentrations of HA, PCS and IS were measured pre- and post-dialysis during baseline (no diuretics) and diuretic treatment phases using high-performance liquid chromatography coupled with tandem mass spectrometry. Changes in pre- and post-dialysis toxin levels were evaluated across treatment phases. Repeated measures analysis of variance assessed the effect of each diuretic treatment on toxin levels and clearance rates.

Results: Both loop diuretics increased the free fraction and clearance of PBUTs compared with baseline. Torasemide demonstrated higher efficacy in enhancing the clearance of HA (76.8%) compared with furosemide (63.2%) and baseline (57.3%). For PCS, furosemide achieved greater reductions (66.3%) than torasemide (61.8%) and baseline (24%). Indoxyl sulfate clearance increased significantly with both diuretics (59.1% for furosemide and 58.8% for torasemide) compared with baseline (26.2%).

Conclusion: This study demonstrates that loop diuretics, especially torasemide, can enhance the clearance of PBUTs during hemodialysis. Their use mobilizes PBUTs from tissue stores and increases their dialyzability. These findings warrant further investigation in larger, long-term studies to validate the efficacy and clinical benefits of this approach.

无尿血液透析患者循环利尿剂清除蛋白结合尿毒症毒素。
背景:在慢性肾脏疾病中,蛋白质结合尿毒症毒素(PBUTs)的积累,如马尿酸(HA)、对甲酰硫酸酯(PCS)和硫酸吲哚酚(IS),有助于全身毒性和器官功能障碍。这些毒素与血浆蛋白(主要是白蛋白)结合,使其无法通过常规透析清除。本研究假设循环利尿剂,特别是托拉塞米和呋塞米,可以将pbut从白蛋白结合位点上取代,增加其游离部分,并在血液透析过程中促进其去除。方法:本前瞻性多中心交叉研究纳入17例来自两家医院的无尿血液透析患者。参与者接受呋塞米和托拉塞米的顺序治疗,每个阶段间隔1周的洗脱期。在基线(无利尿剂)和利尿剂治疗阶段,采用高效液相色谱联用串联质谱法测定透析前后血凝素、PCS和IS的浓度。透析前后毒素水平的变化在各个治疗阶段进行评估。重复测量方差分析评估每种利尿剂治疗对毒素水平和清除率的影响。结果:与基线相比,两种利尿剂都增加了PBUTs的游离分数和清除率。与呋塞米(63.2%)和基线(57.3%)相比,托拉塞米在提高HA清除率方面的疗效更高(76.8%)。对于PCS,呋塞米的降低率(66.3%)高于托拉塞米(61.8%)和基线(24%)。与基线(26.2%)相比,两种利尿剂(速尿组59.1%,托拉塞米组58.8%)显著增加了硫酸吲哚酚清除率。结论:本研究表明,循环利尿剂,特别是托拉塞米,可以提高血液透析过程中PBUTs的清除。它们的使用调动了组织储存中的pbut,并增加了它们的透析性。这些发现值得在更大的长期研究中进一步调查,以验证这种方法的疗效和临床益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Kidney Journal
Clinical Kidney Journal Medicine-Transplantation
CiteScore
6.70
自引率
10.90%
发文量
242
审稿时长
8 weeks
期刊介绍: About the Journal Clinical Kidney Journal: Clinical and Translational Nephrology (ckj), an official journal of the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association), is a fully open access, online only journal publishing bimonthly. The journal is an essential educational and training resource integrating clinical, translational and educational research into clinical practice. ckj aims to contribute to a translational research culture among nephrologists and kidney pathologists that helps close the gap between basic researchers and practicing clinicians and promote sorely needed innovation in the Nephrology field. All research articles in this journal have undergone peer review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信